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ABSTRACT 
Objective: The objective of the present study was to develop and validate a novel stability indicating reverse phase-high performance liquid 
chromatography (RP-HPLC) method for determination of β-acetyldigoxin, an active pharmaceutical ingredient (API).  
Methods: The chromatographic separation was carried out on Agilent Technologies 1200 series HPLC system equipped with photo diode array 
detector and C-18 (4.6x250 mm, 5 µ) column. The mobile phase consisted of water: acetonitrile (65:35 v/v), delivered at a flow rate of 1.5 ml/min 
and eluents were monitored at 225 nm.  
Results: The retention time of β-acetyldigoxin was 9.2 min. The method was found to be linear (R2= 0.9995) in the range of 31.25-500 µg/ml. The 
accuracy studies showed the mean percent recovery of 101.02%. LOD and LOQ were observed to be 0.289 µg/ml and 0.965 µg/ml, respectively. The 
method was found to be robust and system suitability testing was also performed. Forced degradation analysis was carried out under acidic, 
alkaline, oxidative and photolytic stress conditions. Significant degradation was observed under tested conditions, except for oxidative condition. 
The method was able to separate all the degradation products within runtime of 20 min and was able to determine β-acetyldigoxin unequivocally in 
presence of degradation products.  
Conclusion: The novel, economic, rapid and simple method for analysis of β-acetyldigoxin is reported. The developed method is suitable for routine 
quality control and its determination as API, and in pharmaceutical formulations and stability study samples. 
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enolide (fig. 1) [1], is a prodrug of digoxin, a well-established agent 
for managing heart failure and controlling rapid ventricular rate in 

























Fig. 1: Chemical structure-β-Acetyldigoxin [1] 
 
Digoxin affects cardiac rate, rhythm and the force of cardiac 
contraction. It increases vagal activity and slows down conduction in 
the atrioventricular (AV) node. Digoxin binds to the K+-binding site 
of Na+/K+-ATPase pump and increases the force of contraction [4]. 
The acetyl group of β-acetyldigoxin is cleaved on passage through 
intestinal wall and active digoxin reaches the heart [5]. β-
Acetyldigoxin is a substrate of p-glycoprotein and has a similar 
transport mechanism as digoxin [6]. β-Acetyldigoxin is reported to 
have better absorption [7], efficacy and tolerance [8], as compared 
to parent drug, digoxin. Like digoxin, β-acetyldigoxin also belongs to 
the category of narrow therapeutic index drugs [9, 10]. Digoxin and 
β-acetyldigoxin are two of the most important marketed cardiac 
glycosides [11, 12].  
β-Acetyldigoxin-Need for novel stability indicating assay method  
Stability indicating assay method is a validated analytical procedure 
that is able to measure unequivocally the drug substance in presence 
of degradation products [13, 14]. Previously reported HPLC methods 
for analytical determination of β-acetyldigoxin simultaneously with 
related cardiac glycosides, indicate its retention time at 17.3 min 
[15] and 23.4 min [16], respectively. Since elution is quite late, these 
methods aren’t suitable for routine quality control. Also, the 
European Pharmacopoeia HPLC assay method [1] for β-
acetyldigoxin utilizes gradient elution. There are various 
disadvantages associated with gradient elution such as poor 
robustness, longer equilibration periods and complexity of method 
development. The column life is also shortened and method transfer 
is difficult [17]. No stability indicating assay method for forced 
degradation studies, as per regulatory guidelines, has been reported 
for the determination of β-acetyldigoxin.  
The present report describes development and validation of a novel 
and rapid isocratic stability indicating assay method for 
determination of β-acetyldigoxin. 
MATERIALS AND METHODS 
Chemicals and reagents  
Analytical grade β-acetyldigoxin was purchased from Clearsynth 
Labs, Mumbai. HPLC grade solvents (water, methanol, acetonitrile) 
were procured from Loba Chemie and Fischer Scientific. All 
chemicals were analytical grade and were used as supplied.  
Instrumentation 
The RP-HPLC method was developed on Agilent Technologies 1200 
series HPLC system. It was equipped with Agela Technologies C-18 
(4.6x250 mm, 5µ, 100 Å) column, binary pump, photo diode array 
detector, auto sampler and EzChrome Elite software. Digital 
temperature controlled oven (Relitech) and UV chamber (Inco) were 
used for forced degradation studies. 
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Preparation of stock solution  
Accurately weighed β-acetyldigoxin was transferred to volumetric 
flask and volume was made up with methanol: acetonitrile (50:50 
v/v) to obtain a 1000 µg/ml stock solution.  
Optimization of chromatographic conditions  
The detection wavelength for β-acetyldigoxin was selected 
according to European Pharmacopoeia method [1]. The 
chromatographic conditions were optimized to get a sharp and 
symmetric peak. Initial experiments, beginning with water: 
acetonitrile, 50:50 v/v at flow rate of 1.0 ml/min, resulted in 
delayed elution and a broad peak.  
Mobile phase, flow rate and injection volume were optimized to 
get an optimum elution time and a symmetrical sharp peak. The 
run time should be 2.5 times the retention time of peak of 
analyte for optimum analysis of degradation products [13], so 
the run time of 20 min was selected for the study. The mode of 
elution was isocratic and separation was carried out at ambient 
temperature.  
Calibration curve 
The stock solution of β-acetyldigoxin (1000 µg/ml) was serially 
diluted with methanol: acetonitrile (50:50 v/v) to prepare solutions 
with concentration of 31.25, 62.5, 125, 250, 500 µg/ml, respectively. 
Each solution was injected in triplicates to obtain the 
chromatograms. A calibration curve was constructed by plotting 
average peak area versus concentration.  
Method validation and system suitability testing 
The method for analytical determination of β-acetyldigoxin was 
validated and tested for system suitability according to International 
Conference on Harmonization (ICH), United States Food and Drug 
Administration (FDA) and United States Pharmacopoeia (USP) 
guidelines [18-20].  
Linearity 
Linearity was determined by computing correlation coefficient from 
calibration curve, in the range of 31.25–500 µg/ml.  
Precision 
For interday precision studies, analysis was carried out for three 
consecutive days at three different concentrations, 125, 250, 500 
µg/ml respectively, in triplicate. To study intraday precision, 
analysis was carried out at three different times in a day at three 
different concentrations, 125, 250, 500 µg/ml respectively, in 
triplicate. % RSD (relative standard deviation) of peak areas were 
calculated for both the studies.  
Accuracy 
Standard addition method was employed for accuracy studies. 
Spiking was done at levels of 80, 100 and 120 % in previously 
analyzed sample of 250 µg/ml to measure percent recovery by the 
assay of known added amounts of analyte.  
Robustness 
Robustness was measured by making small but deliberate changes 
in detection wavelength (±5 nm), flow rate (±0.1 ml/min.) and 
organic content in mobile phase (±2 units). % RSD of peak areas was 
calculated for each of the evaluations.  
Limit of detection (LOD) and limit of quantification (LOQ) 
The specificity of the method was determined by forced degradation 
studies. LOD and LOQ were determined using the formulas, LOD = 
3.3×σ/S and LOQ = 10×σ/S, where, ‘σ’ is the standard deviation of 
the response and ‘S’ is the slope of calibration curve. 
System suitabilitytesting 
System suitability was evaluated by analyzing six replicates (500 
µg/ml) of β-acetyldigoxin. Suitability for intended use was tested in 
terms of % RSD of retention time, % RSD of peak area, tailing factor 
(Tf), asymmetry factor (As), number of theoretical plates (N) and 
height equivalent to theoretical plates (HETP). 
Specificity-forced degradation studies 
β-acetyldigoxin (1 mg/ml) was subjected to acidic stress (0.1 N 
HCl, 40 °C, 30 min.), alkaline stress (0.1 N NaOH, 40 °C, 30 min.), 
oxidative stress (30 % H2O2, RT, 24 h) and photo stress (UV, 365 
nm, 96 h). The stressed samples were appropriately diluted 
before injection. For each stress condition, three chromatograms 
were recorded, namely; control (analyte not subjected to stress), 
blank (stressor and solvent) and stressed (analyte subjected to 
stress). 
RESULTS AND DISCUSSION  
Chromatographic conditions and calibration curve 
The chromatographic conditions were optimized, after multiple 
trials, to get a symmetric optimum eluting peak. The average 
retention time for β-acetyldigoxin was 9.207±0.031 min. (n=3) 
(fig. 2). Thus, the developed method provides faster elution time 
than the previously reported methods [15, 16].  
The method is isocratic and is thus simple as compared to 
European Pharmacopoeia method [1], and also overcomes the 
limitations of a gradient method [17]. The method is rapid and is 
thus cost effective. The method does not use buffer and therefore, 
various additional steps like pH adjustment [21] are eliminated. 
Also, buffers are aggressive towards column packing and longer 
periods of column washing are needed [22].  
Optimized chromatographic conditions are summed up in table 1. 
An injection of blank (only solvent, no analyte) was also run (fig. 3). 
A calibration curve was (fig. 4) plotted to compute regression 
equation and correlation coefficient. 
  
Table 1: Optimized chromatographic conditions 
S. No. Parameter Condition 
1 Stationary phase Innoval C-18 column (4.6x250 mm, 5µ) 
2 Mobile phase Water: acetonitrile (65:35 v/v) 
3 Flow rate 1.5 ml/min 
4 Detector Photo diode array 
5 Injection volume 5 µl 
6 Detection wavelength 225 nm 
7 Retention Time 9.207 min 
8 Diluent/solvent Methanol: acetonitrile (50:50 v/v) 
9 Run time  20 min 
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Fig. 2: Chromatogram for β-acetyldigoxin showing elution time of 9.207 min 
 
 
Fig. 3: Blank (Methanol: Acetonitrile (50:50 v/v)) does not show any peak around elution time of β-acetyldigoxin 
 
 
Fig. 4: Calibration curve for β-acetyldigoxin for concentration range from 31.25 to 500 µg/ml 
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Method validation and system suitability testing 
The developed method was validated according to regulatory 
guidelines [18-20]. Results of validation and system suitability 
testing are summed up in table 2. The results complied with the 
acceptance criteria laid down under regulatory guidelines [20, 23] 
with % RSD values, tailing factor, asymmetry factor and height 
equivalent to theoretical plates being well below the acceptable 
limits and correlation coefficient, and number of theoretical plates 
were above the minimum acceptance criterion. 
 
Table 2: Method validation and system suitability parameters 
Parameter Observation  Acceptance criterion [20, 23] 
Regression equation y=10354x-16859 - 
Correlation coefficient 0.9995 ≥ 0.995 
Range 31.25-500 µg/ml - 
Average %RSD (Peak area, n=5) (Linearity) 0.20 ≤ 2.0% 
Average %RSD (Peak area, n=3) (Intraday precision) 0.13 ≤ 2.0% 
Average %RSD (Peak area, n=3) (Interday precision) 0.45 ≤ 2.0% 
Average %Recovery (n=3) (Accuracy) 101.02% 100±3% 
Average %RSD (n=6) Peak area (Robustness) 0.34 ≤ 2.0% 
Limit of detection 0.289 µg/ml  Low 
Limit of quantitation 0.965 µg/ml Low 
Average tailing factor 1.45 ≤ 2.0 
Average asymmetry factor 1.63 ≤ 2.0 
%RSD (Peak area, n=6) 0.37 ≤ 1.0% 
%RSD (Retention time, n=6) 0.36 ≤ 1.0% 
Average number of theoretical plates 8876.0 >2000 
Average height equivalent to theoretical plates 0.028 mm <0.1 cm 
 
Forced degradation studies-specificity 
β-Acetyldigoxin was subjected to various stress conditions. The results 
of forced degradation studies are summed up in table 3. β-
Acetyldigoxin was found to be resistant to degradation under 
oxidative stress (percent recovery lying in 100±5% [24]). Whereas, 
significant degradation occurred under all other stress conditions 
tested. The chromatograms of stressed samples are shown in fig. 5-8.  
The peak of β-acetyldigoxin was completely separated from the 
degradation products generated under tested stress conditions. 
There was no interference of any of the degradation products from 
the stress conditions tested in current study with the retention time 
of β-acetyldigoxin. Thus, the developed method for analytical 
determination of β-acetyldigoxin was established to be specific and 
stability-indicating [13].  
 
Table 3: Results of forced degradation studies 
Stress condition Degradation (%) 
0.1 N HCl, 40 °C, 30 min. 44.19 
0.1 N NaOH, 40 °C, 30 min. 56.13 
30% H2O2, RT, 24 h 3.0 




Fig. 5: Chromatogram for β-acetyldigoxin subject to acidic degradation 
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Fig. 6: Chromatogram for β-acetyldigoxin subject to alkaline degradation 
 
 
Fig. 7: Chromatogramfor β-acetyldigoxin subject to oxidative degradation 
 
 
Fig. 8: Chromatogram for β-acetyldigoxin subject to photo degradation 
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A novel RP-HPLC method for analytical determination of β-
acetyldigoxin was developed. It was found to be simple, linear, 
accurate, precise, specific, robust, rapid and suitable for routine quality 
control and determination as API, and in pharmaceutical formulations 
and stability study samples. The peak of β-acetyldigoxin was 
distinguishable and quantifiable among the peaks of degradation 
products under tested stress conditions, thus the method is stability 
indicating. This method can be employed for determination of β-
acetyldigoxin as API, and in pharmaceutical dosage forms and stability 
study samples. The rapidity and simplicity of this method overcomes 
limitations of previously reported methods, and make it suitable for 
routine quality control of β-acetyldigoxin. 
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